HC Wainwright & Co. Reiterates Buy on Freeline Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Freeline Therapeutics (NASDAQ:FRLN) and maintained a $15 price target.
August 17, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Freeline Therapeutics (NASDAQ:FRLN) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $15.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $15 indicates the firm's confidence in the stock's potential to reach this price in the short term. This could lead to increased investor interest and potentially a rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100